SWX:KURNBiotechs
Kuros Biosciences (SWX:KURN) Stock Slips After First Profit Milestone
The market has cooled on Kuros Biosciences over the past week, with the stock down about 5% even as the latest report marks the first profitable half year in the company’s history. That disconnect between a softer share price and a clear profitability milestone is the core sentiment test for investors today.
H1 2026 brought total revenue of US$92.4m and net profit of US$4.4m, backed by a 13.6% adjusted EBITDA margin. For a high growth medtech that only recently crossed into the black, this...